# Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

> **NCT02731469** · PHASE1 · COMPLETED · sponsor: **Biocad** · enrollment: 45 (actual)

## Conditions studied

- Reticulocyte Count

## Interventions

- **BIOLOGICAL:** BCD-131
- **BIOLOGICAL:** Mircera®
- **BIOLOGICAL:** Aranesp®

## Key facts

- **NCT ID:** NCT02731469
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-15
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02731469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02731469, "Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02731469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*